ZA201107649B - Thienopyrimidinedione derivatives as trpa1 modulators - Google Patents

Thienopyrimidinedione derivatives as trpa1 modulators

Info

Publication number
ZA201107649B
ZA201107649B ZA2011/07649A ZA201107649A ZA201107649B ZA 201107649 B ZA201107649 B ZA 201107649B ZA 2011/07649 A ZA2011/07649 A ZA 2011/07649A ZA 201107649 A ZA201107649 A ZA 201107649A ZA 201107649 B ZA201107649 B ZA 201107649B
Authority
ZA
South Africa
Prior art keywords
trpa1 modulators
thienopyrimidinedione
derivatives
thienopyrimidinedione derivatives
trpa1
Prior art date
Application number
ZA2011/07649A
Other languages
English (en)
Inventor
Sukeerthi Kumar
Abraham Thomas
Nayan Taterao Waghmare
Sanjay Margal
Neelima Khairatkar-Joshi
Indranil Mukhopadhyay
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42780205&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201107649(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of ZA201107649B publication Critical patent/ZA201107649B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2011/07649A 2009-03-23 2011-10-19 Thienopyrimidinedione derivatives as trpa1 modulators ZA201107649B (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
IN2213MU2009 2009-09-23
US25199409P 2009-10-15 2009-10-15
IN2906MU2009 2009-12-16
US29447010P 2010-01-12 2010-01-12
PCT/IB2010/000930 WO2010109334A2 (en) 2009-03-23 2010-03-23 Thienopyrimidinedione derivatives as trpa1 modulators

Publications (1)

Publication Number Publication Date
ZA201107649B true ZA201107649B (en) 2012-07-25

Family

ID=42780205

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2011/07649A ZA201107649B (en) 2009-03-23 2011-10-19 Thienopyrimidinedione derivatives as trpa1 modulators
ZA2011/07650A ZA201107650B (en) 2009-03-23 2011-10-19 Furopyrimidinedione derivatives as trpa1 modulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2011/07650A ZA201107650B (en) 2009-03-23 2011-10-19 Furopyrimidinedione derivatives as trpa1 modulators

Country Status (22)

Country Link
US (4) US20120178766A1 (https=)
EP (3) EP2411395B1 (https=)
JP (2) JP2012521406A (https=)
KR (2) KR20110128898A (https=)
CN (3) CN102361874A (https=)
AP (1) AP2948A (https=)
AU (2) AU2010227225A1 (https=)
BR (2) BRPI1013705A2 (https=)
CA (2) CA2756535A1 (https=)
DK (3) DK2411395T3 (https=)
EA (2) EA201190138A1 (https=)
ES (3) ES2424341T3 (https=)
HU (1) HUE024538T2 (https=)
IL (2) IL215177A (https=)
MX (1) MX2011009822A (https=)
PE (2) PE20120834A1 (https=)
PL (3) PL2411395T3 (https=)
PT (3) PT2411395E (https=)
SG (4) SG174398A1 (https=)
SI (3) SI2411395T1 (https=)
WO (2) WO2010109329A1 (https=)
ZA (2) ZA201107649B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2411393T1 (sl) 2009-03-23 2014-03-31 Glenmark Pharmaceuticals S.A. Kondenzirani pirimidin-dionski derivati kot TRPA 1 modulatorji
EP2411395B1 (en) 2009-03-23 2013-05-29 Glenmark Pharmaceuticals S.A. Furopyrimidinedione derivatives as trpa1 modulators
PE20140234A1 (es) * 2010-12-20 2014-03-08 Glenmark Phamaceuticals S A Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
CA2836856A1 (en) * 2011-06-13 2012-12-20 Glenmark Pharmaceuticals, S.A. Treatment of respiratory disorders using trpa1 antagonists
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
BR112013031820A2 (pt) * 2011-06-22 2016-12-13 Glenmark Pharmaceutical S A composições farmacêuticas, incluindo para administração oral e por inalação, usos de quantidade sinergicamente eficaz de antagonista trpa1 e métodos para tratar distúrbios respiratórios e para melhorar a função pulmonar
US20140148423A1 (en) * 2011-07-25 2014-05-29 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a steroid
EP2787991A1 (en) 2011-12-05 2014-10-15 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
SG11201408093PA (en) * 2012-06-08 2015-01-29 Glenmark Pharmaceuticals Sa Amides of 2-amino-4-arylthiazole compounds and their salts
PT2903965T (pt) 2012-10-01 2017-06-06 Orion Corp Derivados de n-prop-2-inilcarboxamida e sua utilização como antagonistas de trpa1
EP3010489A1 (en) 2013-06-20 2016-04-27 Glenmark Pharmaceuticals S.A. Nanoparticulate formulation comprising a trpa1 antagonist
EP3057583A2 (en) 2013-10-15 2016-08-24 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
JP6573968B2 (ja) * 2014-08-11 2019-09-11 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． ＴＲＰＣ５調節因子としての、精神神経障害の処置のためのチエノおよびフロ［２，３−ｄ］ピリミジン−２，４［１Ｈ，３Ｈ］−ジオン誘導体
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
WO2016023825A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
WO2016028325A1 (en) 2014-08-22 2016-02-25 Duke University Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2016042501A1 (en) * 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
CN109310683A (zh) * 2016-04-07 2019-02-05 杜克大学 用于消毒和麻醉的trpv4和trpa1的小分子双重抑制剂
WO2018162607A1 (en) * 2017-03-07 2018-09-13 F. Hoffmann-La Roche Ag Oxadiazole transient receptor potential channel inhibitors
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
JP7612682B2 (ja) 2019-10-15 2025-01-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なテトラゾール
CN116348471B (zh) * 2020-10-14 2025-10-31 勃林格殷格翰国际有限公司 作为trpa1抑制剂的四唑衍生物
AU2021363101A1 (en) * 2020-10-14 2023-03-23 Boehringer Ingelheim International Gmbh Tetrazole derivatives as TRPA1 inhibitors
CN116940575A (zh) * 2021-02-23 2023-10-24 深圳市康哲药业有限公司 噻吩并嘧啶二酮类化合物及其应用
AU2022257269A1 (en) 2021-04-14 2023-08-17 Boehringer Ingelheim International Gmbh 3H,4H-THIENO[2,3-d]PYRIMIDIN-4-ONE DERIVATIVES AS TRPA1 INHIBITORS
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DE69912618T2 (de) * 1998-08-28 2004-10-28 Astrazeneca Ab NEUE THIENO[2,3-d]PYRIMIDINDIONE, VERFAHREN FÜR IHRE HERSTELLUNG UND IHRE VERWENDUNG IN DER THERAPIE
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
AR043057A1 (es) * 2002-10-30 2005-07-13 Vertex Pharma Compuestos derivados de piridintiazoles como inhibidores de la quinasa rock y otras proteinas quinasa
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
WO2004055054A1 (en) 2002-12-18 2004-07-01 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
EP1657238A4 (en) 2003-08-22 2008-12-03 Takeda Pharmaceutical CONDENSATE PYRIMIDINE DERIVATIVE AND ITS USE
WO2005077959A1 (en) * 2004-02-11 2005-08-25 Smithkline Beecham Corporation Pth agonists
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
EP1847541A4 (en) * 2005-02-03 2009-12-30 Takeda Pharmaceutical CONDENSED PYRIMIDINE DERIVATIVE AND USE THEREOF
US20070032531A1 (en) * 2005-08-04 2007-02-08 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
CN101351463A (zh) * 2005-11-08 2009-01-21 欧加农股份有限公司 用于治疗trpv1相关病症的2-(苯并咪唑-1-基)-n-(4-苯基噻唑-2-基)乙酰胺衍生物
WO2007054480A1 (en) * 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
US20070105920A1 (en) * 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
AU2006327181A1 (en) 2005-12-22 2007-06-28 Hydra Biosciences, Inc. TRPA1 inhibitors for treating pain
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
ES2609912T3 (es) 2007-06-22 2017-04-25 Hydra Biosciences, Inc. Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1
WO2009002983A1 (en) * 2007-06-25 2008-12-31 Sandisk Corporation Non-volatile storage with individually controllable shield plates between storage elements
US7951814B2 (en) 2008-06-17 2011-05-31 Glenmark Pharmaceuticals, S.A. Quinazolinedione derivatives as TRPA1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
EP2411395B1 (en) 2009-03-23 2013-05-29 Glenmark Pharmaceuticals S.A. Furopyrimidinedione derivatives as trpa1 modulators
WO2010109328A1 (en) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
ES2426407T3 (es) 2009-10-15 2013-10-23 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2539170T3 (es) 2010-01-12 2015-06-26 Ab Science Inhibidores de quinasas de oxazol
DK2483255T3 (da) 2010-07-13 2014-01-20 Novartis Ag Oxazinderivater samt deres anvendelse ved behandling af neurologiske lidelser

Also Published As

Publication number Publication date
DK2411396T3 (da) 2013-08-05
US20150150876A1 (en) 2015-06-04
CN102361874A (zh) 2012-02-22
PT2411396E (pt) 2013-06-06
AU2010227230A1 (en) 2011-09-22
AU2010227230A2 (en) 2011-10-27
BRPI1013705A2 (pt) 2016-04-05
AU2010227230B2 (en) 2015-11-26
PL2411396T3 (pl) 2013-10-31
CA2756535A1 (en) 2010-09-30
IL215175A (en) 2014-01-30
WO2010109334A3 (en) 2010-11-25
EA022029B1 (ru) 2015-10-30
EA201190139A1 (ru) 2012-03-30
WO2010109329A1 (en) 2010-09-30
US9474758B2 (en) 2016-10-25
PE20120834A1 (es) 2012-07-25
ZA201107650B (en) 2012-07-25
EA201190138A1 (ru) 2013-05-30
ES2424341T3 (es) 2013-10-01
PT2411395E (pt) 2013-06-06
IL215175A0 (en) 2011-12-29
SG174404A1 (en) 2011-10-28
IL215177A (en) 2014-01-30
ES2532386T3 (es) 2015-03-26
EP2634191A1 (en) 2013-09-04
JP5612070B2 (ja) 2014-10-22
CN102361877A (zh) 2012-02-22
DK2411395T3 (da) 2013-08-05
AU2010227225A1 (en) 2011-09-15
SG184767A1 (en) 2012-10-30
EP2411396B1 (en) 2013-05-29
PL2634191T3 (pl) 2015-06-30
CN103755720A (zh) 2014-04-30
KR20120004422A (ko) 2012-01-12
CN103755720B (zh) 2016-07-06
SI2634191T1 (sl) 2015-04-30
US8507503B2 (en) 2013-08-13
KR20110128898A (ko) 2011-11-30
PT2634191E (pt) 2015-03-04
HK1166073A1 (en) 2012-10-19
IL215177A0 (en) 2011-12-29
US20120295924A1 (en) 2012-11-22
EP2411395A1 (en) 2012-02-01
JP2012521406A (ja) 2012-09-13
SG174398A1 (en) 2011-10-28
HUE024538T2 (hu) 2016-01-28
CA2756536C (en) 2015-10-06
BRPI1009381B8 (pt) 2021-05-25
PL2411395T3 (pl) 2013-10-31
BRPI1009381B1 (pt) 2020-04-14
CN102361877B (zh) 2014-05-07
US20120178766A1 (en) 2012-07-12
EP2411396A2 (en) 2012-02-01
SI2411395T1 (sl) 2013-07-31
CA2756536A1 (en) 2010-09-30
SG184769A1 (en) 2012-10-30
KR101524337B1 (ko) 2015-05-29
WO2010109334A2 (en) 2010-09-30
US8987278B2 (en) 2015-03-24
JP2012521407A (ja) 2012-09-13
EP2411395B1 (en) 2013-05-29
EP2634191B1 (en) 2014-12-24
DK2634191T3 (en) 2015-03-23
PE20120775A1 (es) 2012-06-27
AP2011005889A0 (en) 2011-10-31
SI2411396T1 (sl) 2013-07-31
ES2424342T3 (es) 2013-10-01
BRPI1009381A2 (pt) 2016-06-21
MX2011009822A (es) 2012-01-25
US20130289054A1 (en) 2013-10-31
AU2010227225A2 (en) 2011-10-06
AP2948A (en) 2014-07-31
HK1166074A1 (en) 2012-10-19

Similar Documents

Publication Publication Date Title
AP2948A (en) Thienopyrmidinedione derivatives as TRPA1 modulators
ZA201107646B (en) Isothiazolo-prrimidinedione derivatives as trpa1 modulators
AP3280A (en) Fused pyrimidine-dione derivatives as TRPA1 modulators
IL219087A0 (en) Benzimidazole-imidazole derivatives
IL217956A0 (en) N1-sulfonyl-5-fluoropyrimidinone derivatives
IL217953A0 (en) 5-fluoropyrimidinone derivatives
IL215169A0 (en) Isoxazole -pyridine derivatives as gaba modulators
IL216007A0 (en) Isoxazole-pyridine derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
IL214941A0 (en) Isoxazole-pyrazole derivatives
IL217952A0 (en) N1-acyl-5-fluoropyrimidinone derivatives
IL213927A0 (en) Deoxyactagardine derivatives
IL216761A0 (en) Pyrazinooxazepine derivatives
GB0921967D0 (en) Novel Aryloxyanilide Derivatives
IL213262A0 (en) Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en) Indopyl-pyridone derivatives
AP2011005883A0 (en) Furopyrimidinedione derivatives as TRPA1 modulators.